Patient Cooperation Committee
Basic Policy
As the committee closest to and most knowledgeable about patient groups, one of the most important stakeholders in realizing patient-participatory drug discovery, the JPMA will deepen mutual understanding with patient groups and cooperation with other committees within the JPMA, and contribute to the promotion of co-creation by multi-stakeholders to solve common problems that will lead to win-win situations. （Contribute to the promotion of co-creation by multi-stakeholders toward win-win solutions to common problems.
Priority Issues
-
Identify common issues between JPMA and patient groups and consider solutions
-
Create opportunities for dialogue and mutual understanding between JPMA and patient groups, as well as other multi-stakeholder groups including medical professionals, academia, and government/authorities.
-
To improve the sense of purpose, mindset, knowledge and manner in which the members of this committee and related committees interact and collaborate with patient groups
-
Assist patient groups to better understand Patient and Public Engagement (PPI/E) and to promote collaboration with other stakeholders.
Priority Tasks to be addressed
-
To gain an understanding of the current status of patient groups, their challenges, and expectations of JPMA through discussions and information exchange at the Patient Group Advisory Board, as well as through interviews and surveys conducted in collaboration with patient groups.
-
To share the current status and issues of JPMA and patient groups, as well as the efforts and issues of both committees, and to serve as a hub to consider and implement cooperative measures within JPMA and multi-stakeholder collaborative measures to resolve issues.
-
To serve as the secretariat of the "Society for Creating a Society with Easy Access to Clinical Trials for All" (hereinafter referred to as "Creation Society"), which was established by multi-stakeholders, and to promote activities to resolve issues related to access to clinical trials.
-
To serve as the secretariat of the "Pharmaceutical Visionary Council," a multi-stakeholder group, and to promote dialogue and mutual understanding, as well as to promote initiatives to resolve common issues.
-
To provide JPMA's activities and proposals in an easy-to-understand manner, while disseminating necessary information to patient groups through the JPMA Newsletter, website, and other media, as well as at the "Creation Meeting", "Pharmaceutical Visionary Meeting", "JPMA Forum", "Patient Group Advisory Board", and other events.
-
Provide learning opportunities for members of the Committee and related committees to review and improve their awareness of purpose, mindset, knowledge, and mannerisms when interacting and collaborating with patient groups.
-
Ensure that member companies continue to understand and implement the Guidelines for Working with Patient Groups and the Transparency Guideline for the Relationship between Corporate Activities and Patient Groups.
-
Continuously discuss and consider ways to collaborate with patient groups and new initiatives to resolve common issues at the Patient Groups Advisory Board, Chairperson Leaders' Meetings, and task forces.
Other Activity Plans
None in particular
Collaboration with other committees
-
Collaborate with the Drug Evaluation Committee, the Pharmaceutical Industrial Policy Committee, the Public Affairs Committee, and others to resolve issues discussed at the Creation Meeting and the Pharmaceutical Visionary Conference.
-
Collaborate with other related committees as needed (Code Compliance Committee, International Affairs Committee, R & D Committee, ICH Project, Consumer Consultation Review Committee, etc.).
-
Provide opportunities to exchange views and share information with leaders of committees in industry associations other than JPMA who are in charge of patient groups, as necessary, depending on the issue.